Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Högner

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Oncology Research and Treatment|November 8, 2021
Multiple Myeloma: Molecular Pathogenesis and Disease EvolutionMichael Heider, Katharina Nickel, Marion Högner, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 26, 2025
ALyzer3D.AI: a more generalizable deep learning predictor of light chain amyloidogenicity powered by structural and evolutionary Artificial IntelligencePeter May, Johannes Jung, Marion Högner, et al.
Annals of Hematology|November 9, 2025
Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practiceHeinz Ludwig, Elias K Mai, Marion Högner, et al.
Transfusion|April 11, 2024
Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysisVeronika Dill, Philipp Blüm, Anja Lindemann, et al.
Vaccines|August 29, 2024
Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine ResponseKrischan Braitsch, Samuel D Jeske, Jacob Stroh, et al.
Leukemia|March 25, 2026
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myelomaJohannes Waldschmidt, David Fandrei, Judith S Hecker, et al.
Blood|July 10, 2025
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane AntigensLeonie Rieger, Kilian Irlinger, Franziska Füchsl, et al.
Hemasphere|April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myelomaJan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Oncology Research and Treatment|November 8, 2021
Multiple Myeloma: Molecular Pathogenesis and Disease EvolutionMichael Heider, Katharina Nickel, Marion Högner, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 26, 2025
ALyzer3D.AI: a more generalizable deep learning predictor of light chain amyloidogenicity powered by structural and evolutionary Artificial IntelligencePeter May, Johannes Jung, Marion Högner, et al.
Annals of Hematology|November 9, 2025
Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practiceHeinz Ludwig, Elias K Mai, Marion Högner, et al.
Transfusion|April 11, 2024
Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysisVeronika Dill, Philipp Blüm, Anja Lindemann, et al.
Vaccines|August 29, 2024
Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine ResponseKrischan Braitsch, Samuel D Jeske, Jacob Stroh, et al.
Leukemia|March 25, 2026
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myelomaJohannes Waldschmidt, David Fandrei, Judith S Hecker, et al.
Blood|July 10, 2025
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane AntigensLeonie Rieger, Kilian Irlinger, Franziska Füchsl, et al.
Hemasphere|April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myelomaJan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Pageof 1